The names on this page are hidden. Create a free account to reveal 5 records a month, or get Private Equity Intelligence at $249 a month for every name. Every figure, date and source on this page is public either way.

Transactions / L••••••

NOV '21 W••••, C•••••, A••••••• & S•••• Acquires Majority Stake in L••••••, A 503B Outsourced Pharmaceutical Compounding Industry Leader, in Partnership with Leading Health Systems

Majority investmentclosedannounced Nov 9, 2021closed Nov 9, 2021Fact
What happened
Target
L••••••
Platform
not an add-on on record
Control
Control
Share acquired
unknown
Industry
business_services / outsourc
Target location
unknown
Seller kind
unknown
Rollover
unknown
Values, only where disclosed
Enterprise value
Not disclosed
Purchase price
Not disclosed
Equity value
Not disclosed
Target revenue
Not disclosed
Target EBITDA
Not disclosed
Multiple
Not disclosed
Parties and roles
4 named
Buy side
  • N••• O••••••Deal partnerconfirmed
    “N••• O••••••, General Partner at WCAS, said, "We are very excited about our investment in L••••••.”
  • W•••• C••••• A••••••• • S••••Sponsorconfirmed
    “W•••• C••••• A••••••• • S•••• (WCAS), a leading private equity firm focused exclusively on the healthcare and technology industries, announced today it has acquired a majority ownership stake in L••••••, a rapidly growing leader in the FDA-regulated 503B outsourced pharmaceutical compounding industr”
Advisory side
  • C••••• F••••••••• • C••Sell-side adviserconfirmed
    “C••••• F••••••••• • C•• served as financial advisor to L•••••• in connection with the transaction.”
Side not stated
  • L••••••Targetconfirmed
    “W•••• C••••• A••••••• • S•••• (WCAS), a leading private equity firm focused exclusively on the healthcare and technology industries, announced today it has acquired a majority ownership stake in L••••••, a rapidly growing leader in the FDA-regulated 503B outsourced pharmaceutical compounding industr”
Evidence
“W•••• C••••• A••••••• • S•••• (WCAS), a leading private equity firm focused exclusively on the healthcare and technology industries, announced today it has acquired a majority ownership stake in L••••••, a rapidly growing leader in the FDA-regulated 503B outsourced pharmaceutical compounding industry.”
Press release wires (PR Newswire, GlobeNewswire, Business Wire public pages and RSS)confidence 80%recorded Sep 16, 2026